Download PDF
Thromb Haemost 2005; 93(03): 544-548
DOI: 10.1160/TH04-07-0428
Platelets and Blood Cells
Schattauer GmbH

The FcγRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIbα and FcγRIIa and a risk for thromboembolism in lupus anticoagulant patients

Katharina Schallmoser
1   Clinic for Blood Group Serology, Medical University of Vienna
2   Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Graz
,
Christiane Rosin
1   Clinic for Blood Group Serology, Medical University of Vienna
,
Regina Knittelfelder
1   Clinic for Blood Group Serology, Medical University of Vienna
,
Thomas Sailer
3   Department of Internal Medicine, Division of Haematology and Haemostaseology
,
Silvia Ulrich
2   Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Graz
,
Claudia Zoghlami
3   Department of Internal Medicine, Division of Haematology and Haemostaseology
,
Stephan Lehr
4   Department of Medical Computer Sciences – Clinical Biometrics, Medical University Vienna, Austria
,
Ingrid Pabinger
3   Department of Internal Medicine, Division of Haematology and Haemostaseology
,
Simon Panzer
1   Clinic for Blood Group Serology, Medical University of Vienna
› Author AffiliationsGrant support: This work was supported in part by a Grant from the Hochschuljubiläumsstiftung der Stadt Wien and by Grant 8647 from the österreichische Nationalbank to Simon Panzer.
Further Information

Publication History

Received 15 July 2004

Accepted after resubmission 03 January 2005

Publication Date:
14 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

There is a clear propensity of individuals with lupus anticoagulant (LA) for thromboembolic disease (TE). Yet, it is not clear how individuals at risk for TE can be differentiated from those who are not. The FcγRIIa receptor is the only Fc receptor expressed by platelets. As platelets can be activated via this receptor, we have compared gene frequencies of the FcγRIIa polymorphism R/H131 in 46 and 27 patients with (LA/TE+) and without TE (LA/TE-), respectively, in an exploratory study. Furthermore, we investigated the presence of autoantibodies against FcγRIIa and/or GPIbα, which is in close proximity to the FcγRIIa and interacts with it functionally, and a possible linkage of antibody formation to HLA class II alleles. The FcγRIIa-R/R131 genotype was significantly less frequent in patients with LA compared to controls (p< 0.025). These findings were due to an increased frequency of heterozygous patients in the LA/TE+ cohort (odds ratio 6.76, 95% confidence interval 1.55 – 62.03, p< 0.008). For the first time, heterozygosity, rather than homozygosity, can be linked to disease, which may be explained by the dual function of the FcγRIIa, namely binding of antibodies to platelets and thereby their activation, and, on the other hand, clearance of antibody coated platelets by the phagocyte system. There was no correlation between the presence of anti-FcγRIIa or anti GPIbα autoantibodies and the FcγRIIa -R/H131 polymorphism, nor the incidence of TE, nor HLA class II alleles.

Keywords

Lupus anticoagulant - FcγRIIa receptor - GPIbα - thromboembolic disease
 

  • References

  • 1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
    CrossrefPubMedGoogle Scholar
  • 2 Levine JS. et al. The anti-phospholipid syndrome. N Engl J Med 2002; 346: 752-63.
    CrossrefPubMedGoogle Scholar
  • 3 Joseph JE, Harrison P, Mackie IJ. et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-9.
    CrossrefPubMedGoogle Scholar
  • 4 Cassel DL, Keller MA, Surrey S. et al. Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: analysis of transcripts. Mol Immunol 1993; 30: 451-60.
    CrossrefPubMedGoogle Scholar
  • 5 Sullam PM. et al. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor Fcγ RIIA on the platelet plasma membrane. J Biol Chem 1998; 273: 5331-6.
    CrossrefPubMedGoogle Scholar
  • 6 Clark MR, Clarkson SB, Ory PA. et al. Molecular Basis for a Polymorphism Involving Fc Receptor II on Human Monocytes. J Immunol 1989; 143: 1731-4.
    PubMedGoogle Scholar
  • 7 Warmerdam PA, Van de Winkel JGJ, Gosselin EJ. et al. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J Exp Med 1990; 172: 19-25.
    CrossrefPubMedGoogle Scholar
  • 8 Warmerdam PA, Van de Winkel JG, Vlug A. et al. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338-43.
    PubMedGoogle Scholar
  • 9 Parren PW, Warmerdam PA, Boeije LC. et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90: 1537-46.
    CrossrefPubMedGoogle Scholar
  • 10 Sammaritano LR. et al. Anticardiolipin IgG Subclasses. Arthritis Rheum 1997; 40: 1998-2006.
    CrossrefPubMedGoogle Scholar
  • 11 Out HJ, de Groot PG, van Vliet M. et al. Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 1991; 77: 2655-9.
    PubMedGoogle Scholar
  • 12 Fabris F. et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232-6.
    PubMedGoogle Scholar
  • 13 Galli M. et al. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994; 71: 571-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Panzer S, Pabinger I, Gschwandtner ME. et al. Lupus anticoagulants: strong association with the major histocompatibility complex class II and platelet antibodies. Br J Haematol 1997; 98: 342-5.
    CrossrefPubMedGoogle Scholar
  • 15 Panzer S, Gschwandtner ME, Hütter D. et al. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Ann Hematol 1997; 74: 239-42.
    CrossrefPubMedGoogle Scholar
  • 16 Niessner H, Clemetson KJ, Panzer S. et al. Acquired thrombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 1986; 68: 571-76.
    PubMedGoogle Scholar
  • 17 Olsson A, Andersson PO, Tengborn L. et al. Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function. Thromb Res 2002; 15 107: 135-9.
    CrossrefPubMedGoogle Scholar
  • 18 Kekomaki R. Platelet function and immune response. J Pediatr Hematol Oncol 2003; 25: 19-23.
    CrossrefPubMedGoogle Scholar
  • 19 Boylan B, Chen H, Rathore V. et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ - chain complex from the human platelet surface. Blood 2004; 104: 1350-55.
    CrossrefPubMedGoogle Scholar
  • 20 Canobbio I, Bertoni A, Lova P. et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem 2001; 276: 26022-9.
    CrossrefPubMedGoogle Scholar
  • 21 Cauwenberghs N. et al. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor. Thromb Haemost 2001; 85: 679-85.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the SSC of the ISTH. Thromb Haemost 1995; 74: 1185-90.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Wenzel C, Stoiser B, Locker GJ. et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 2002; 30: 763-70.
    CrossrefPubMedGoogle Scholar
  • 24 Carlsson LE. et al. Heparin-induced thrombocytopenia: new insights into the impact of the Fc γ RIIa- R-H131 polymorphism. Blood 1998; 92: 1526-31.
    CrossrefPubMedGoogle Scholar
  • 25 Flesch BK, Bauer F, Neppert J. Rapid typing of the human Fc gamma receptor IIA polymorphism by polymerase chain reaction amplification with allelespecific primers. Transfusion 1998; 38: 174-76.
    CrossrefPubMedGoogle Scholar
  • 26 Kiefel V, Santoso S, Weisheit M. et al. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of plateletreactive antibodies. Blood 1987; 70: 1722-6.
    PubMedGoogle Scholar
  • 27 Fischer GF, Faé I, Pickl WF. Distribution of polymorphic HLA-DR and –DQ alleles as determined by restriction fragment length polymorphism analysis in an Austrian population. Vox Sang 1992; 62: 236-41.
    PubMedGoogle Scholar
  • 28 De Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr 2001; 113: 825-31.
    PubMedGoogle Scholar
  • 29 Macchi L, Rispal P, Clofent-Sanchez G. et al. Antiplatelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98: 336-41.
    CrossrefPubMedGoogle Scholar
  • 30 Arnett FC. et al. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 1999; 42: 268-74.
    CrossrefPubMedGoogle Scholar
  • 31 Bertolaccini ML. et al. Association of antiphosphatidylserine/ prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 2000; 43: 683-8.
    CrossrefPubMedGoogle Scholar
  • 32 Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin- induced thrombocytopenia. Thromb Haemost 1996; 75: 536-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Taylor SM. et al. Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor. Blood 2000; 96: 4254-60.
    PubMedGoogle Scholar
  • 34 Duits AJ. et al. Skewed distribution of IgG Fc Receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995; 39: 1832-6.
    PubMedGoogle Scholar
  • 35 Salmon JE, Millard S. et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-54.
    CrossrefPubMedGoogle Scholar
  • 36 Kiefel V, Spaeth P, Mueller-Eckhardt C. Immune thrombocytopenic purpura: autoimmune or immune complex disease?. Br J Haematol 1986; 64: 57-68.
    CrossrefPubMedGoogle Scholar
  • 37 Karassa FB, Bijl M, Davies KA. et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48: 1930-8.
    CrossrefPubMedGoogle Scholar
  • 38 Blasini AM. et al. Increased proportion of responders to a murine anti-CD3 monoclonal antibody of the IgG1 class in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1993; 94: 423-8.
    PubMedGoogle Scholar
  • 39 Rascu A. et al. Clinical relevance of Fcγ receptor polymorphisms. Ann NY Acad Sci 1997; 815: 282-95.
    CrossrefPubMedGoogle Scholar
  • 40 Miescher S, Spycher MO, Amstutz H. et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc γ RIIA and Fcγ IIIA genes. Blood, 2004; 103: 4028-35.
    CrossrefPubMedGoogle Scholar
  • 41 Carcao MD. et al. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120: 135-41.
    CrossrefPubMedGoogle Scholar